David Allan is the recipient of the 2017 Julia Levy Award recognizing successful commercialization of innovation in the field of Bio-medical Science and Engineering,  the 2016 Leadership Award from Life Sciences Ontario and the 2012 Gold Leaf Award for Industry Leadership from Canada's industry association BIOTECanada.



​Appointed to the Board of eQcell Inc, 2021; the Advisory Board of Inteligex, Inc, 2020 and the Advisory Board of Haygain, Ltd in 2019. He was, most recently, the founding chairman of Forbius, acquired by Bristol Myers Squibb in 2020; Executive Chairman of Stem Cell Therapeutics Inc, (Trillium Therapeutics) purchased by Pfizer in 2021; and the founding and sunset Chairman, and CEO from 1998 to 2011, of YM BioSciences Inc. until its acquisition by Gilead Sciences in 2013.

Cresswell Advisors
David G P Allan Life Sciences and Financial advisor nimotuzumab pediatric glioma LSO

Previously a Governor of the Toronto Stock Exchange, he has been a member of the Ontario Biotechnology Advisory Board, the Awards Selection Committee of Canada's Network of Centers of Excellence and the Multidisciplinary Assessment Committee of the Canada Foundation for Innovation.

David Allan, Cresswell, CIM, Miyar
Biotec Canada
Stem Cell Therapeutics
nimotuzumab, centro inmunologia molecular, CIM, glioma, Jose M. Miyar, OFAC
Life Sciences Ontario
Trillium Therapeutics